{"id":10212,"date":"2026-07-10T09:06:51","date_gmt":"2026-07-10T14:06:51","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10212"},"modified":"2026-07-10T09:14:18","modified_gmt":"2026-07-10T14:14:18","slug":"nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina de 2026."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10212\" class=\"elementor elementor-10212\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><i>Jordi Mon\u00e9s, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration<\/i><\/li><li><i>Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b\/3 Trial of MCO-010 in Retinitis Pigmentosa<\/i><\/li><\/ul><p><strong><span class=\"legendSpanClass\">MONTREAL<\/span>,\u00a0<span class=\"legendSpanClass\">July 10, 2026<\/span><\/strong>\u00a0 &#8212; Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that clinical data from its optogenetic therapy programs will be featured at the <b>American Society of Retina Specialists (ASRS) 44<sup>th<\/sup>\u00a0Annual Scientific Meeting, taking place July 15\u201318, 2026, at the Palais des Congr\u00e8s de Montr\u00e9al in Montreal, Canada.<\/b><\/p><p>The presentations will highlight Nanoscope&#8217;s entry into age-related macular degeneration (AMD) with a new clinical trial of optogenetic therapy in geographic atrophy (GA) evaluating vision improvement, and long-term durability data for MCO-010 in retinitis pigmentosa (RP).<\/p><p><b>Detalles de la presentaci\u00f3n:<\/b><\/p><p><b>T\u00edtulo:<\/b>\u00a0<i>Vision Improvement with Sonpiretigene Isteparvovec Optogenetic Therapy in Macular Degeneration: First Direct-to-Phase 2 Randomized, Controlled Trial<\/i><\/p><p><b>Presentador:<\/b>\u00a0Jordi Mon\u00e9s, Doctor en Medicina, Doctor en Filosof\u00eda<br \/><b>Sesi\u00f3n:<\/b>\u00a0AMD \u2013 Non-neovascular Symposium 1: &#8220;Beyond Atrophy: Restoring Vision and Redefining Care in Geographic Atrophy&#8221;<br \/><b>Date &amp; Time:<\/b>\u00a0Thursday, July 16 | 1:46 PM<\/p><p><b>T\u00edtulo:<\/b>\u00a0<i>Durable Vision Improvement with MCO-010 Optogenetic Therapy: 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b\/3 Trial for Retinitis Pigmentosa<br \/><\/i><b>Presentador:<\/b>\u00a0Benjamin Bakall, MD, PhD<br \/><b>Format:<\/b>\u00a0Paper-on-Demand Presentation<\/p><p><b>Acerca de la plataforma MCO<br \/><\/b>Multi-characteristic opsin (MCO) is a one-time, in-office, intravitreal disease-agnostic therapy platform designed to restore vision in patients with photoreceptor degeneration, including Retinitis Pigmentosa (RP), Stargardt disease (SD), and geographic atrophy (GA). By activating highly dense bipolar retinal cells to become light sensitive, MCO utilizes the remaining visual circuitry following photoreceptor death. MCO treatment does not require genetic testing, invasive surgery, or repeat dosing, enabling broad patient applicability within existing retina office workflows.<\/p><p><b>Acerca de Nanoscope Therapeutics<br \/><\/b>Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b\/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), a BLA has been submitted to the FDA. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in SD (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations to cover non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has received Sakigake and orphan designations for inherited retinal dystrophies (IRDs) in Japan and an orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in GA is expected to start in 2026. Other IND-ready programs include Leber congenital amaurosis (LCA).<\/p><p>Contacto:<br class=\"dnr\" \/>Nanoscope Therapeutics, Inc<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Jordi Mon\u00e9s, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b\/3 Trial of MCO-010 in Retinitis Pigmentosa MONTREAL,\u00a0July 10, 2026\u00a0 &#8212; Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-10T14:06:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-10T14:14:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting\",\"datePublished\":\"2026-07-10T14:06:51+00:00\",\"dateModified\":\"2026-07-10T14:14:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"wordCount\":497,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"datePublished\":\"2026-07-10T14:06:51+00:00\",\"dateModified\":\"2026-07-10T14:14:18+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-07-10T14:06:51+00:00","article_modified_time":"2026-07-10T14:14:18+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting","datePublished":"2026-07-10T14:06:51+00:00","dateModified":"2026-07-10T14:14:18+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"},"wordCount":497,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","name":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","datePublished":"2026-07-10T14:06:51+00:00","dateModified":"2026-07-10T14:14:18+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10212"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212\/revisions"}],"predecessor-version":[{"id":10220,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212\/revisions\/10220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10213"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}